A research team based in Vancouver and directed by the most cited neuroscientist of Canada, Dr Patrick McGeer, has effectively conducted research signifying that, if initiated early enough, an everyday dose of the non-prescription nonsteroidal anti-inflammatory drug (NSAID) ibuprofen can thwart the commencement of Alzheimer’s disease. This implies that by having an OTC medicine, individuals can keep a disease at bay that, as per the World Alzheimer Report 2016 of Alzheimer’s Disease International, impacts an anticipated 47 Million individuals globally, expenses health care systems globally over US$818 Billion each year and is the 5th leading reason for demise in those aged 65 or more.
Dr. McGeer and his colleagues, in 2016, declared that they had come up with an easy saliva test that could analyze Alzheimer’s disease and also envisage its future start. The test relies on evaluating the quantity of the Abeta42 (peptide amyloid β protein 42) exuded in saliva.
In the majority of people, the Abeta 42 production rate is almost precisely the same irrespective of age or sex. Nevertheless, if that production rate is 2–3 times greater, those people are fated to develop Alzheimer’s disease. This is as Abeta42 is a comparatively insoluble substance and even though it is produced all over in the body, accumulation of it happens in the brain only, resulting in neuroinflammation that devastates neurons within the brains of individuals with Alzheimer’s disease.
In contrast to the extensively held conviction that Abeta 42 is produced in the brain only, Dr. McGeer’s team confirmed that the peptide is produced in all the body organs and is oozed in saliva from the submandibular gland. Consequently, with as slight as 1 teaspoon of saliva, it is feasible to envisage whether that person is doomed to develop Alzheimer’s disease. This provides them a chance to start taking early precautionary steps such as intake of non-prescription NSAID such as ibuprofen.